约翰·霍普金斯大学的研究人员开发了四种使用FDA批准的抗生素治疗耐多药结核性脑膜炎的方案。 Researchers at Johns Hopkins developed four regimens for treating multidrug-resistant TB meningitis using FDA-approved antibiotics.

约翰霍普金斯儿童中心的研究人员开发了四种新疗法来治疗多抗药性结核性脑膜炎 (MDR),主要使用FDA批准的临床试验抗生素. Researchers at Johns Hopkins Children's Center have developed four new regimens for treating multidrug-resistant (MDR) tuberculous (TB) meningitis, primarily using FDA-approved and clinical trial antibiotics. 这些疗法可以在新的临床研究中随时加以评价,或逐案使用,显示出治疗MDR-TB脑膜炎的希望,这是一种具有挑战性的疾病形式。 The regimens, which could be readily evaluated in new clinical studies or used on a case-by-case basis, show promise in treating MDR-TB meningitis, which is a challenging form of the disease. 这项研究利用对病人、兔子和小鼠的PET和CT成像来显示不同的抗生素如何渗透到大脑和其他身体领域。 The study utilized PET and CT imaging on patients, rabbits, and mice to demonstrate how different antibiotics penetrate the brain and other body areas.